https://www.pharmaradar360.com/article/maharashtra-fda-cracks-down-on-milk-adulteration-issues-stricter-norms-for-suppl-c87a25f682e22c61Pharma Surgeen2026-07-03T16:17:56.000ZMaharashtra FDA cracks down on milk adulteration, issues stricter norms for supply chainhttps://www.pharmaradar360.com/article/geodis-achieves-iata-ceiv-pharma-certification-in-india-fa1d29850ba420f9Pharma Surgeen2026-07-03T15:34:34.000ZGeodis achieves IATA CEIV Pharma certification in Indiahttps://www.pharmaradar360.com/article/ebola-disease-caused-by-bundibugyo-virus-democratic-republic-of-the-congo-uganda-c4d5032dd170748bPharma Surgeen2026-07-03T15:13:57.000ZEbola disease caused by Bundibugyo virus, Democratic Republic of the Congo & Ugandahttps://www.pharmaradar360.com/article/pharmaceutical-companies-increasingly-use-celebrity-ambassadors-for-direct-to-co-1cd5410434a52317Pharma Surgeen2026-07-03T14:55:29.000ZPharmaceutical Companies Increasingly Use Celebrity Ambassadors for Direct-to-Consumer Marketinghttps://www.pharmaradar360.com/article/the-celebrity-prescription-star-power-meets-healthcare-fccc3c92df149e2ePharma Surgeen2026-07-03T14:42:31.000ZThe celebrity prescription: star power meets healthcarehttps://www.pharmaradar360.com/article/disclosure-uk-2025-the-11th-year-of-disclosure-uk-data-with-industry-transparenc-4e954cfb9b0f2c0cPharma Surgeen2026-07-03T14:13:25.000ZDisclosure UK 2025: the 11th year of Disclosure UK data, with industry transparency continuing to growhttps://www.pharmaradar360.com/article/glenmark-advances-multi-country-phase-3-clinical-trial-of-trastuzumab-rezetecan-c3b153202d0e4e9cPharma Surgeen2026-07-03T14:04:41.000ZGlenmark Advances Multi-Country Phase 3 Clinical Trial of Trastuzumab rezetecan in Platinum-Resistant Ovarian Cancerhttps://www.pharmaradar360.com/article/structure-therapeutics-gpcr-is-a-hidden-biotech-multibagger-stock-to-buy-now-98a4c1afac37a679Pharma Surgeen2026-07-03T13:41:31.000ZStructure Therapeutics (GPCR) Is A Hidden Biotech Multibagger Stock To Buy Nowhttps://www.pharmaradar360.com/article/fda-progress-could-send-this-biotech-stock-soaring-to-new-heights-eba4a8ff458b1f97Pharma Surgeen2026-07-03T13:40:34.000ZFDA Progress Could Send This Biotech Stock Soaring To New Heightshttps://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-nanjing-well-pharmaceutical-group-co-ltd-c-3217cb79dcccc2aaPharma Surgeen2026-07-03T13:22:42.000ZEnterprise value to EBITDA forward of Nanjing Well Pharmaceutical Group Co. Ltd. Class A – SSE:603351https://www.pharmaradar360.com/article/gea-invests-4m-in-new-technology-center-for-scaling-biotech-and-new-food-process-8853434664544033Pharma Surgeen2026-07-03T13:18:26.000ZGEA Invests €4M in New Technology Center for Scaling Biotech and New Food Processeshttps://www.pharmaradar360.com/article/laprophan-acquires-majority-stake-in-swiss-pharmaceutical-firm-rivopharm-928d1c90103a28f8Pharma Surgeen2026-07-03T13:03:56.000ZLaprophan Acquires Majority Stake in Swiss Pharmaceutical Firm Rivopharmhttps://www.pharmaradar360.com/article/arcutis-vs-vertex-which-pharmaceutical-maker-stock-is-a-better-buy-in-2026-56f5dce1fcdc9a72Pharma Surgeen2026-07-03T12:54:03.000ZArcutis vs. Vertex: Which Pharmaceutical Maker Stock Is a Better Buy in 2026?https://www.pharmaradar360.com/article/air-pollution-awareness-coalition-apac-e917c85b4ebb88d0Pharma Surgeen2026-07-03T12:53:05.000ZAir Pollution Awareness Coalition (APAC)https://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-meribank-biotech-co-ltd-tpex-4724-c1ecb97299acfeb2Pharma Surgeen2026-07-03T12:28:33.000ZEnterprise value to EBITDA forward of Meribank Biotech Co Ltd – TPEX:4724https://www.pharmaradar360.com/article/sihuan-pharmaceutical-holdings-group-sehk-460-following-phase-iii-trial-progress-aecdce9eecd76dc9Pharma Surgeen2026-07-03T12:23:52.000ZSihuan Pharmaceutical Holdings Group (SEHK:460) Following Phase III Trial Progress Is The Stock Too Priceyhttps://www.pharmaradar360.com/article/omni-tract-surgical-retractor-system-ab06fa9278057036Pharma Surgeen2026-07-03T12:00:00.000ZOmni-Tract Surgical Retractor Systemhttps://www.pharmaradar360.com/article/dlp-select-3d-arterial-cannula-and-dlp-elongated-one-piece-arterial-cannulae-48efec877469eb60Pharma Surgeen2026-07-03T12:00:00.000ZDLP Select 3D Arterial Cannula and DLP Elongated One Piece Arterial Cannulaehttps://www.pharmaradar360.com/article/astrazeneca-pens-1-7b-kidney-drug-discovery-pact-with-go-to-chinese-partner-cspc-04f22b7e7642ca0dPharma Surgeen2026-07-03T12:00:00.000ZAstraZeneca pens $1.7B kidney drug discovery pact with go-to Chinese partner CSPChttps://www.pharmaradar360.com/article/ebola-and-marburg-returning-workers-scheme-rws-0b1c8da0eb5eb1f7Pharma Surgeen2026-07-03T11:59:28.000ZEbola and Marburg: returning workers scheme (RWS)https://www.pharmaradar360.com/article/trust-spot-biotech-growth-soars-21-3i-group-regroups-after-may-slump-seraphim-sp-afe7835bd9c11b64Pharma Surgeen2026-07-03T11:59:21.000ZTrust Spot: Biotech Growth soars 21%; 3i Group regroups after May slump; Seraphim Space steps back from highhttps://www.pharmaradar360.com/article/ebola-and-marburg-haemorrhagic-fevers-outbreaks-and-case-locations-16b29cdb0bb31831Pharma Surgeen2026-07-03T11:57:22.000ZEbola and Marburg haemorrhagic fevers: outbreaks and case locationshttps://www.pharmaradar360.com/article/biib-stock-ends-3-higher-why-this-strategist-picks-biogen-over-other-biotech-pee-c961ecccbe965512Pharma Surgeen2026-07-03T11:51:46.000ZBIIB Stock Ends 3% Higher — Why This Strategist Picks Biogen Over Other Biotech Peershttps://www.pharmaradar360.com/article/biotech-catalyst-impending-rpn-closure-and-age-old-funding-conundrums-f9d6598cf46dc719Pharma Surgeen2026-07-03T11:49:51.000ZBiotech catalyst, impending RPN closure and age-old funding conundrumshttps://www.pharmaradar360.com/article/phosgene-market-growth-fueled-by-rising-demand-from-chemical-and-pharmaceutical-81dec8e9250b6a0cPharma Surgeen2026-07-03T11:34:24.000ZPhosgene Market Growth Fueled by Rising Demand from Chemical and Pharmaceutical Industrieshttps://www.pharmaradar360.com/article/uk-clinical-trials-performance-improves-but-remains-in-intensive-care-a298a3ad9a104fc9Pharma Surgeen2026-07-03T11:28:36.000ZUK clinical trials performance improves but remains in intensive carehttps://www.pharmaradar360.com/article/regulatory-renewal-needed-for-uk-life-sciences-ambitions-4bb95ab3c88fbca4Pharma Surgeen2026-07-03T11:28:21.000ZRegulatory renewal needed for UK life sciences ambitionshttps://www.pharmaradar360.com/article/abpi-welcomes-the-innovation-ecosystem-programme-review-46b77369fdf73babPharma Surgeen2026-07-03T11:28:06.000ZABPI welcomes the Innovation Ecosystem Programme Reviewhttps://www.pharmaradar360.com/article/abpi-welcomes-the-appointment-of-new-mhra-chair-0045e7cbe2a718acPharma Surgeen2026-07-03T11:27:54.000ZABPI welcomes the appointment of new MHRA Chairhttps://www.pharmaradar360.com/article/the-king-s-fund-calls-on-nhs-leaders-to-help-unlock-power-of-industry-partnershi-d170cb97c94f00d3Pharma Surgeen2026-07-03T11:27:42.000ZThe King’s Fund calls on NHS leaders to help unlock power of industry partnershipshttps://www.pharmaradar360.com/article/uk-missing-opportunity-to-unlock-medicines-for-severe-conditions-f7c2666360bf279cPharma Surgeen2026-07-03T11:27:28.000ZUK missing opportunity to unlock medicines for severe conditionshttps://www.pharmaradar360.com/article/abpi-response-to-sudlow-review-on-the-use-of-health-data-d153e9c792109121Pharma Surgeen2026-07-03T11:27:08.000ZABPI response to Sudlow review on the use of health datahttps://www.pharmaradar360.com/article/abpi-welcomes-the-chancellor-s-backing-of-life-sciences-in-the-budget-a21c3f1a93e42589Pharma Surgeen2026-07-03T11:26:57.000ZABPI welcomes the Chancellor’s backing of life sciences in the Budgethttps://www.pharmaradar360.com/article/fixing-nhs-needs-greater-investment-in-medicines-says-abpi-f3b5db066ae74260Pharma Surgeen2026-07-03T11:26:39.000ZFixing NHS needs greater investment in medicines, says ABPIhttps://www.pharmaradar360.com/article/mps-and-peers-urge-chancellor-to-support-the-life-sciences-in-budget-26e43c1f2dfded60Pharma Surgeen2026-07-03T11:26:28.000ZMPs and peers urge Chancellor to support the life sciences in Budgethttps://www.pharmaradar360.com/article/partnerships-build-trust-between-industry-and-healthcare-professionals-3b1cae059684032cPharma Surgeen2026-07-03T11:26:15.000ZPartnerships build trust between industry and healthcare professionalshttps://www.pharmaradar360.com/article/labour-budget-can-unlock-uk-life-science-opportunities-5a57fdc873f8915aPharma Surgeen2026-07-03T11:26:04.000ZLabour budget can unlock UK life science opportunitieshttps://www.pharmaradar360.com/article/emerging-research-points-to-nhs-and-industry-being-a-successful-partnership-for-084a390e85ec9e51Pharma Surgeen2026-07-03T11:25:50.000ZEmerging research points to NHS and industry being a successful partnership for patientshttps://www.pharmaradar360.com/article/abpi-response-to-united-nations-general-assembly-political-declaration-on-antimi-418ed7232035cd56Pharma Surgeen2026-07-03T11:25:19.000ZABPI response to United Nations General Assembly political declaration on antimicrobial resistancehttps://www.pharmaradar360.com/article/hani-friedman-bouganim-on-industrial-sovereignty-and-ai-in-pharmaceutical-manufa-b00a6099969764dbPharma Surgeen2026-07-03T11:25:09.000ZHani Friedman Bouganim on Industrial Sovereignty and AI in Pharmaceutical Manufacturinghttps://www.pharmaradar360.com/article/government-must-free-nice-to-unlock-access-to-medicines-for-severe-conditions-9af7da482b3b83f8Pharma Surgeen2026-07-03T11:25:08.000ZGovernment must free NICE to unlock access to medicines for severe conditionshttps://www.pharmaradar360.com/article/abpi-welcomes-chancellor-s-speech-at-labour-party-conference-fb622a0b234a1e7fPharma Surgeen2026-07-03T11:24:55.000ZABPI welcomes Chancellor’s speech at Labour party conferencehttps://www.pharmaradar360.com/article/2024-abpi-code-of-practice-launched-with-a-new-constitution-and-procedure-for-th-cfd9a85ec3843c7ePharma Surgeen2026-07-03T11:24:44.000Z2024 ABPI Code of Practice launched, with a new constitution and procedure for the PMCPAhttps://www.pharmaradar360.com/article/pm-says-life-sciences-is-a-key-partner-to-fixing-the-nhs-50ad590883c497bePharma Surgeen2026-07-03T11:24:31.000ZPM says life sciences is a key partner to fixing the NHShttps://www.pharmaradar360.com/article/abpi-response-to-the-darzi-review-innovation-must-be-at-the-heart-of-improvement-ae4f510da8723e75Pharma Surgeen2026-07-03T11:24:13.000ZABPI response to the Darzi Review: innovation must be at the heart of improvementhttps://www.pharmaradar360.com/article/sanofi-facility-in-waterford-receives-fda-warning-a57d264334f91496Pharma Surgeen2026-07-03T11:19:00.000ZSanofi facility in Waterford receives FDA warninghttps://www.pharmaradar360.com/article/imm-pe-calls-off-talks-to-acquire-cgbio-from-daewoong-pharmaceutical-s-owner-b614c6a1551632f1Pharma Surgeen2026-07-03T11:18:22.000ZIMM PE calls off talks to acquire CGBio from Daewoong Pharmaceutical’s ownerhttps://www.pharmaradar360.com/article/gea-invests-4m-in-german-biotech-pilot-centre-to-accelerate-food-production-scal-78e71b98c76d8538Pharma Surgeen2026-07-03T10:45:19.000ZGEA invests €4m in German biotech pilot centre to accelerate food production scale-uphttps://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-12-july-2026-26cc426849ce7d62Pharma Surgeen2026-07-03T10:34:32.000ZWeekly all-cause mortality surveillance: week ending 12 July 2026https://www.pharmaradar360.com/article/how-has-the-ukraine-shock-hit-clinical-trials-in-the-region-14d0bfb3121405c3Pharma Surgeen2026-07-03T10:17:38.000ZHow has the Ukraine shock hit clinical trials in the region?https://www.pharmaradar360.com/article/astrazeneca-and-cspc-add-renal-disease-to-rna-pact-run-c700762bf02e2614Pharma Surgeen2026-07-03T10:17:38.000ZAstraZeneca and CSPC add renal disease to RNA pact runhttps://www.pharmaradar360.com/article/kimball-steps-up-pharma-cdmo-push-with-helvoet-buy-4a53cd4528a9c1d5Pharma Surgeen2026-07-03T10:17:38.000ZKimball steps up pharma CDMO push with Helvoet buyhttps://www.pharmaradar360.com/article/pakistan-seeks-chinese-assistance-to-expand-next-cpec-phase-to-pharma-biotech-se-0969d3fb8e5d9a4dPharma Surgeen2026-07-03T10:11:25.000ZPakistan seeks Chinese assistance to expand next CPEC phase to pharma, biotech sectorshttps://www.pharmaradar360.com/article/arthur-cox-advises-on-pharmaceutical-sector-acquisition-64c3df1a5de6d934Pharma Surgeen2026-07-03T10:07:50.000ZArthur Cox advises on pharmaceutical sector acquisitionhttps://www.pharmaradar360.com/article/united-therapeutics-pays-140m-for-thymic-cell-therapy-startup-40fa14b50a64a946Pharma Surgeen2026-07-03T09:49:11.000ZUnited Therapeutics pays $140M for thymic cell therapy startuphttps://www.pharmaradar360.com/article/respiratory-biotech-celea-raises-180m-and-other-financings-26058cb0cd9e135cPharma Surgeen2026-07-03T09:34:29.000ZRespiratory biotech Celea raises $180m, and other financingshttps://www.pharmaradar360.com/article/2026-926ec18134a40c70Pharma Surgeen2026-07-03T09:28:49.000ZΓενόσημα Απριλίου 2026 _ Προτεινόμενες Τιμές προς Διαβούλευσηhttps://www.pharmaradar360.com/article/abivax-sa-abvx-nasdaq-uc-data-fuels-biotech-opportunity-7392838f094c20d5Pharma Surgeen2026-07-03T09:26:01.000ZAbivax SA (ABVX:NASDAQ) UC Data Fuels Biotech Opportunityhttps://www.pharmaradar360.com/article/satellos-bioscience-fast-track-win-fuels-dmd-hopes-c2ff12754d40043bPharma Surgeen2026-07-03T09:26:01.000ZSatellos Bioscience Fast Track Win Fuels DMD Hopeshttps://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-5-july-2026-c41fc7be1a6143d8Pharma Surgeen2026-07-03T09:18:19.000ZWeekly all-cause mortality surveillance: week ending 5 July 2026https://www.pharmaradar360.com/article/erkexin-275401f8d21119acPharma Surgeen2026-07-03T09:16:56.000ZERKEXIN / (ΣΙΛΔΕΝΑΦΙΛΗ, ΤΑΛΑΔΑΦΙΛΗ)https://www.pharmaradar360.com/article/mdd-class-iia-8059b94a2cab71baPharma Surgeen2026-07-03T09:03:14.000ZΑνάκληση των παρτίδων του παρακάτω πίνακα, του Ιατροτεχνολογικού προϊόντος κατηγορίας MDD Class IIa, Αρτηριακές κάνουλες ΕΟΡΑhttps://www.pharmaradar360.com/article/transthera-completes-late-stage-trial-enrollment-for-tinengotinib-cancer-drug-c3bc03f721a3f11ePharma Surgeen2026-07-03T09:02:45.000ZTransThera completes late-stage trial enrollment for Tinengotinib cancer drughttps://www.pharmaradar360.com/article/newron-charts-course-forward-for-stalled-schizophrenia-drug-95574cb1fe5ee06aPharma Surgeen2026-07-03T09:01:41.000ZNewron charts course forward for stalled schizophrenia drughttps://www.pharmaradar360.com/article/109980699-110143347-1739994-mdd-class-i-adapter-for-head-positioning-538f8473eb42a65dPharma Surgeen2026-07-03T08:57:08.000ZΑνάκληση των σειριακών αριθμών 109980699 και 110143347 του κωδικού 1739994, του Ιατροτεχνολογικού προϊόντος MDD Class I, Adapter for Head positioning (εξάρτημα προσαρμογής για τοποθέτηση κεφαλής).https://www.pharmaradar360.com/article/kissei-pharmaceutical-ordered-to-report-on-deaths-among-tavneos-users-067baa5c1435a8cdPharma Surgeen2026-07-03T08:52:07.000ZKissei Pharmaceutical Ordered to Report on Deaths among Tavneos Usershttps://www.pharmaradar360.com/article/amgen-fights-to-keep-avacopan-on-market-amid-rising-concerns-87d4a4b0eb8eaad8Pharma Surgeen2026-07-03T08:40:51.000ZAmgen Fights to Keep Avacopan on Market Amid Rising Concernshttps://www.pharmaradar360.com/article/investment-bank-flags-key-novo-nordisk-metrics-as-potential-market-surprise-3d3ed25af449b283Pharma Surgeen2026-07-03T08:23:26.000ZInvestment bank flags key Novo Nordisk metrics as potential market surprisehttps://www.pharmaradar360.com/article/guidance-best-practice-in-the-labelling-and-packaging-of-medicines-d44247d0dc295239Pharma Surgeen2026-07-03T08:17:56.000ZGuidance: Best practice in the labelling and packaging of medicineshttps://www.pharmaradar360.com/article/guidance-submit-changes-to-labels-and-patient-information-leaflets-as-a-self-cer-05d8caed45ba4b2bPharma Surgeen2026-07-03T08:15:43.000ZGuidance: Submit changes to labels and Patient Information Leaflets as a self-certificationhttps://www.pharmaradar360.com/article/startup-island-taiwan-led-delegation-secures-more-than-100-business-meetings-at-0de993c9d7bd5224Pharma Surgeen2026-07-03T08:03:00.000ZStartup Island TAIWAN-Led Delegation Secures More Than 100 Business Meetings at BIO 2026, Expanding Global Opportunities for Taiwanese Biotech Startupshttps://www.pharmaradar360.com/article/fda-mifepristone-review-could-affect-telehealth-access-74536303cf31e378Pharma Surgeen2026-07-03T08:00:00.000ZFDA Mifepristone Review Could Affect Telehealth Accesshttps://www.pharmaradar360.com/article/measles-mumps-or-rubella-mmr-referral-form-b8efaad36bd5f2a9Pharma Surgeen2026-07-03T07:39:33.000ZMeasles, mumps or rubella (MMR) referral formhttps://www.pharmaradar360.com/article/our-governance-e19412108cc777acPharma Surgeen2026-07-03T07:38:19.000ZOur governancehttps://www.pharmaradar360.com/article/a-new-wave-of-bridging-borders-how-us-asia-biotech-leverages-hybrid-models-to-re-d7538203073eb71aPharma Surgeen2026-07-03T07:33:28.000ZA New Wave of Bridging Borders: How US-Asia Biotech Leverages Hybrid Models to Rewrite the Rules of the Gamehttps://www.pharmaradar360.com/article/west-pharmaceutical-services-stock-10-day-winning-spree-stock-climbs-13-4c6642747cfce98fPharma Surgeen2026-07-03T07:26:52.000ZWest Pharmaceutical Services Stock 10-Day Winning Spree: Stock Climbs 13%https://www.pharmaradar360.com/article/abbvie-shares-phase-3-cll14-trial-data-for-venetoclax-combination-faa6dfd426b66212Pharma Surgeen2026-07-03T07:22:39.000ZAbbVie Shares Phase 3 CLL14 Trial Data for Venetoclax Combinationhttps://www.pharmaradar360.com/article/west-pharmaceutical-services-stock-10-day-winning-spree-stock-climbs-13-844857d9e3ceaf45Pharma Surgeen2026-07-03T07:20:50.000ZWest Pharmaceutical Services Stock 10-Day Winning Spree: Stock Climbs 13%https://www.pharmaradar360.com/article/food-additives-and-gras-substances-a-legal-framework-d84302e88919d0c0Pharma Surgeen2026-07-03T07:19:05.000ZFood Additives and GRAS Substances: A Legal Frameworkhttps://www.pharmaradar360.com/article/register-based-study-suggests-a-slightly-increased-risk-of-meningiomas-in-women-bc26b80888780993Pharma Surgeen2026-07-03T07:14:00.000ZRegister-based study suggests a slightly increased risk of meningiomas in women using hormonal contraception containing a progestogenhttps://www.pharmaradar360.com/article/towa-pharmaceutical-co-ltd-notice-of-acquisition-of-shares-of-tanabe-pharma-fact-e730d78aef09414ePharma Surgeen2026-07-03T07:01:35.000ZTowa Pharmaceutical Co Ltd - Notice Of Acquisition Of Shares Of Tanabe Pharma Factory And Transfer Of Manufacturing And Marketing Approvalshttps://www.pharmaradar360.com/article/price-to-book-forward-of-guizhou-yibai-pharmaceutical-co-ltd-class-a-sse-600594-16e955897b843697Pharma Surgeen2026-07-03T06:26:47.000ZPrice to book forward of Guizhou Yibai Pharmaceutical Co. Ltd. Class A – SSE:600594https://www.pharmaradar360.com/article/how-one-pharmaceutical-company-charted-a-path-to-success-501311d950e10b7dPharma Surgeen2026-07-03T06:24:41.000ZHow one pharmaceutical company charted a path to successhttps://www.pharmaradar360.com/article/global-biotech-m-a-shows-signs-of-recovery-clinical-data-and-efficacy-emerge-as-dffea09c9349a19dPharma Surgeen2026-07-03T06:19:24.000ZGlobal Biotech M&A Shows Signs of Recovery, Clinical Data and Efficacy Emerge as Key Deal-Breakershttps://www.pharmaradar360.com/article/protected-cell-and-gene-therapy-patents-what-s-accelerating-what-s-lagging-behin-5c1382e0bfd233d5Pharma Surgeen2026-07-03T06:16:59.000ZProtected: Cell and gene therapy patents: What’s accelerating, what’s lagging behindhttps://www.pharmaradar360.com/article/huons-completes-merger-to-strengthen-pharma-biotech-businesses-811827b69150211cPharma Surgeen2026-07-03T04:54:58.000ZHuons completes merger to strengthen pharma, biotech businesseshttps://www.pharmaradar360.com/article/fosun-pharma-to-invest-27-5-mil-in-aribio-after-ar1001-licensing-deal-f7f455c0ca9fedc8Pharma Surgeen2026-07-03T04:20:34.000ZFosun Pharma to invest $27.5 mil. in AriBio after AR1001 licensing dealhttps://www.pharmaradar360.com/article/fda-steps-up-import-enforcement-action-on-infant-formula-cantaloupes-and-seafood-8b9118f34f88aa45Pharma Surgeen2026-07-03T04:02:12.000ZFDA steps up import enforcement action on infant formula, cantaloupes and seafoodhttps://www.pharmaradar360.com/article/axsm-vs-alny-which-biotech-has-the-dna-of-a-millionaire-maker-24dbdc71eab79421Pharma Surgeen2026-07-03T03:26:10.000ZAXSM vs. ALNY: Which Biotech Has the DNA of a Millionaire-Maker?https://www.pharmaradar360.com/article/newron-provides-update-following-type-a-meeting-with-the-fda-f586a646448e2f74Pharma Surgeen2026-07-03T03:10:54.000ZNewron Provides Update Following Type A Meeting With the FDAhttps://www.pharmaradar360.com/article/takeda-s-new-ai-drug-discovery-deal-with-insilico-might-change-the-case-for-inve-dc8f070892023d03Pharma Surgeen2026-07-03T02:12:00.000ZTakeda’s New AI Drug Discovery Deal With Insilico Might Change The Case For Investing In Takeda Pharmaceutical (TSE:4502)https://www.pharmaradar360.com/article/biotech-focused-hedge-funds-back-talawar-s-fast-moving-spac-merger-96a110f81ffb43d0Pharma Surgeen2026-07-03T02:11:10.000ZBiotech-Focused Hedge Funds Back Talawar’s Fast Moving SPAC Mergerhttps://www.pharmaradar360.com/article/italy-pharmaceutical-lab-equipment-market-analysis-forecast-size-trends-and-insi-8c65e448d14aff1bPharma Surgeen2026-07-03T01:59:58.000ZItaly Pharmaceutical Lab Equipment - Market Analysis, Forecast, Size, Trends and Insightshttps://www.pharmaradar360.com/article/gpcr-stock-news-today-earnings-events-price-alerts-d695630bce6d5ce9Pharma Surgeen2026-07-03T01:34:32.000ZGPCR Stock News Today | Earnings, Events & Price Alertshttps://www.pharmaradar360.com/article/myasthenia-gravis-pipeline-2026-key-companies-moa-roa-and-clinical-trials-evalua-ab88e178e353d1b0Pharma Surgeen2026-07-03T00:30:22.000ZMyasthenia Gravis Pipeline 2026: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Alpine Immune Science, Toleranzia, Cabaletta Bio, Rallybio, Alexion Pharma, Takedahttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-12b3f8b2a8d4e424Pharma Surgeen2026-07-03T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-1c85598c3af29a8cPharma Surgeen2026-07-03T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b91463-crore-consolidated-revenue-and-e2-82-b9517-9-crore-of-4b9c50d15336f4bePharma Surgeen2026-07-03T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-14dc312e4396621bPharma Surgeen2026-07-03T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-4768b373f7365ebdPharma Surgeen2026-07-03T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-1fb9561064dce61dPharma Surgeen2026-07-03T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-f7515d0b65112eb1Pharma Surgeen2026-07-03T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-aca22e6b7ee757e9Pharma Surgeen2026-07-03T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-announces-launch-of-its-everolimus-tablets-1-mg-generic-of-zortress-f6df4042c12bec55Pharma Surgeen2026-07-03T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-7d4eb1b19d7328edPharma Surgeen2026-07-03T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-feaf207fa939f7b2Pharma Surgeen2026-07-03T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-46b6088dbd3fd054Pharma Surgeen2026-07-03T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/adcock-ingram-completes-delisting-from-jse-natco-pharma-acquires-35-75-stake-493e403309df3dbaPharma Surgeen2026-07-03T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/home-page-bceb3984d3381be5Pharma Surgeen2026-07-03T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/jyong-biotech-showcases-botanical-drug-portfolio-at-bio-2026-international-conve-5f2431d757e51a38Pharma Surgeen2026-07-03T00:00:00.000ZJyong Biotech Showcases Botanical Drug Portfolio at BIO 2026 International Conventionhttps://www.pharmaradar360.com/article/symposium-report-stakeholders-perspectives-on-phase-1-trials-in-japanese-prior-t-bbf69573f696a6cbPharma Surgeen2026-07-03T00:00:00.000ZSymposium Report: Stakeholders' Perspectives on Phase 1 Trials in Japanese Prior to Multi-Regional Clinical Trials and Future Pathways.https://www.pharmaradar360.com/article/recent-advances-in-physicochemical-properties-and-applications-of-schiff-bases-a-25c88552d8406389Pharma Surgeen2026-07-03T00:00:00.000ZRecent Advances in Physicochemical Properties and Applications of Schiff Bases and Heterocyclic Drug Systemshttps://www.pharmaradar360.com/article/clinical-relevant-immunosuppressive-drugs-differentially-modulate-axonal-outgrow-b260b2578f58c3ffPharma Surgeen2026-07-03T00:00:00.000ZClinical Relevant Immunosuppressive Drugs Differentially Modulate Axonal Outgrowth from Human Stem Cell Derived Neuronshttps://www.pharmaradar360.com/article/a-comprehensive-review-of-generative-ai-applications-in-drug-safety-1f556d5ed0dd115bPharma Surgeen2026-07-03T00:00:00.000ZA Comprehensive Review of Generative AI Applications in Drug Safetyhttps://www.pharmaradar360.com/article/greek-terms-in-anatomical-terminology-historical-development-and-implications-fo-a40d88e0db53d52fPharma Surgeen2026-07-03T00:00:00.000ZGreek terms in anatomical terminology: Historical development and implications for medical and pharmaceutical educationhttps://www.pharmaradar360.com/article/trial-of-labor-after-cesarean-and-vaginal-birth-after-cesarean-a-systematic-revi-d66621d545a5704aPharma Surgeen2026-07-03T00:00:00.000ZTrial of Labor After Cesarean and Vaginal Birth After Cesarean: A Systematic Review and Meta-Analysis of Maternal and Neonatal Outcomeshttps://www.pharmaradar360.com/article/patient-specific-subperiosteal-implants-for-oral-and-maxillofacial-rehabilitatio-eb34dd20ffc9214aPharma Surgeen2026-07-03T00:00:00.000ZPatient-Specific Subperiosteal Implants for Oral and Maxillofacial Rehabilitation: A Scoping Review Across Indications, from Established Full-Arch Use to Emerging Single-Tooth and Oncologic Applicationshttps://www.pharmaradar360.com/article/from-pain-relief-to-multidimensional-outcomes-a-structured-narrative-review-of-s-bb81bc97fc117b2bPharma Surgeen2026-07-03T00:00:00.000ZFrom Pain Relief to Multidimensional Outcomes: A Structured Narrative Review of Success Language in a PubMed/MEDLINE Spinal Cord Stimulation Corpushttps://www.pharmaradar360.com/article/oral-food-supplement-with-bio-activated-silicium-and-vitamins-d3-and-k2-in-the-c-3472435fad27995bPharma Surgeen2026-07-03T00:00:00.000ZOral Food Supplement with Bio-Activated Silicium and Vitamins D3 and K2 in the Conservative Management of Osteoporotic Vertebral Compression Fractureshttps://www.pharmaradar360.com/article/association-of-comprehensive-geriatric-assessment-with-knowledge-and-technique-r-b5b70ed85756ea14Pharma Surgeen2026-07-03T00:00:00.000ZAssociation of Comprehensive Geriatric Assessment with Knowledge- and Technique-Related Eye Drop Adherence Problems in Glaucoma Assessed Using the Shimane University Glaucoma Eye Drop Adherence Questionnairehttps://www.pharmaradar360.com/article/pleural-management-pathways-and-outcomes-in-haematological-malignancy-associated-977b99ca9cbccc56Pharma Surgeen2026-07-03T00:00:00.000ZPleural Management Pathways and Outcomes in Haematological Malignancy-Associated Malignant Pleural Effusionhttps://www.pharmaradar360.com/article/perspective-on-lessons-not-learned-from-coley-s-toxins-to-microbial-drug-deliver-a38848571ab3e9b2Pharma Surgeen2026-07-03T00:00:00.000ZPerspective on Lessons Not Learned: From Coley’s Toxins to Microbial Drug Delivery, Guidance for Institutional Review Boards (IRBs)https://www.pharmaradar360.com/article/maxillary-tuberosity-fractures-a-structured-narrative-review-and-clinical-decisi-549d8d22af4ac4efPharma Surgeen2026-07-03T00:00:00.000ZMaxillary Tuberosity Fractures: A Structured Narrative Review and Clinical Decision-Making Considerationshttps://www.pharmaradar360.com/article/clinical-validation-of-4k-three-dimensional-exoscope-system-in-stapedotomy-a-ret-b112105ee627fe90Pharma Surgeen2026-07-03T00:00:00.000ZClinical validation of 4K three-dimensional exoscope system in stapedotomy: a retrospective cohort studyhttps://www.pharmaradar360.com/article/clinical-significance-of-a-flattening-index-derived-from-the-flow-volume-loop-3f53551dfce6d2ddPharma Surgeen2026-07-03T00:00:00.000ZClinical significance of a flattening index derived from the flow-volume loophttps://www.pharmaradar360.com/article/clinical-implementation-of-an-automated-vmat-treatment-planning-script-for-head-a27411ea1806d8dcPharma Surgeen2026-07-03T00:00:00.000ZClinical implementation of an automated VMAT treatment planning script for head and neck cancer patients: three-year experiencehttps://www.pharmaradar360.com/article/bridging-clinical-integration-and-regulatory-compliance-in-3d-printing-a-hybrid-b86043862289075ePharma Surgeen2026-07-03T00:00:00.000ZBridging clinical integration and regulatory compliance in 3D printing: a hybrid model for university-based manufacturing of custom-made medical deviceshttps://www.pharmaradar360.com/article/epitranscriptomic-regulation-by-m6a-in-immunity-and-autoimmune-disorders-emergin-8795a253c1c888f2Pharma Surgeen2026-07-03T00:00:00.000ZEpitranscriptomic regulation by m6A in immunity and autoimmune disorders: emerging mechanisms and clinical perspectiveshttps://www.pharmaradar360.com/article/transfer-rna-expression-modification-and-derived-small-rnas-in-cancer-biology-an-d0be3039d63d8ed4Pharma Surgeen2026-07-03T00:00:00.000ZTransfer RNA expression, modification, and derived small RNAs in cancer biology and clinical potentialhttps://www.pharmaradar360.com/article/clinical-characteristics-and-outcomes-of-severe-legionella-pneumophila-pneumonia-120a4d3e4e9ad630Pharma Surgeen2026-07-03T00:00:00.000ZClinical characteristics and outcomes of severe Legionella pneumophila pneumonia diagnosed by metagenomic next-generation sequencing in children: a case series of 8 patientshttps://www.pharmaradar360.com/article/pattern-based-clinical-recognition-of-diabetes-associated-mucormycosis-an-eviden-f3680dc48af6fee5Pharma Surgeen2026-07-03T00:00:00.000ZPattern-based clinical recognition of diabetes-associated mucormycosis: an evidence mapping study integrating symptom clustering and diagnostic pathwayshttps://www.pharmaradar360.com/article/biomimetic-gradient-hydrogels-for-osteochondral-regeneration-from-multi-dimensio-9078e88e01d74b34Pharma Surgeen2026-07-03T00:00:00.000ZBiomimetic gradient hydrogels for osteochondral regeneration: from multi-dimensional design to clinical translationhttps://www.pharmaradar360.com/article/peer-review-report-for-protocol-for-a-trial-based-economic-evaluation-analysis-o-cc5b063497a1a6cePharma Surgeen2026-07-03T00:00:00.000ZPeer Review Report For: Protocol for a trial-based economic evaluation analysis of a complex digital health intervention including a computerised decision support tool: the iFraP intervention [version 2; peer review: 1 approved, 1 approved with reservations]https://www.pharmaradar360.com/article/applications-of-lasers-in-oral-medicine-14254a78865b092fPharma Surgeen2026-07-03T00:00:00.000ZApplications of Lasers in Oral Medicinehttps://www.pharmaradar360.com/article/the-role-of-chrononutrition-in-type-2-diabetes-obesity-and-night-shift-workers-b2132d5088714ae4Pharma Surgeen2026-07-03T00:00:00.000ZThe Role of Chrononutrition in Type 2 Diabetes, Obesity and Night Shift Workershttps://www.pharmaradar360.com/article/energy-efficient-communication-protocols-for-iot-devices-in-nextgeneration-wirel-d91cecaf07be3185Pharma Surgeen2026-07-03T00:00:00.000ZEnergy-Efficient Communication Protocols for IoT Devices in NextGeneration Wireless Networkshttps://www.pharmaradar360.com/article/iot-based-environmental-monitoring-enhancing-energy-efficiency-through-edge-comp-57b5af47d5f2f00cPharma Surgeen2026-07-03T00:00:00.000ZIoT-Based Environmental Monitoring: Enhancing Energy Efficiency Through Edge Computing Integrationhttps://www.pharmaradar360.com/article/preoperative-anxiety-among-patients-undergoing-elective-surgery-in-a-tertiary-ca-c7b06caa3fea5789Pharma Surgeen2026-07-03T00:00:00.000ZPreoperative Anxiety Among Patients Undergoing Elective Surgery in A Tertiary Care Centre – A Descriptive Cross-Sectional Studyhttps://www.pharmaradar360.com/article/comparative-evaluation-of-opioid-free-versus-opioid-based-anaesthesia-in-patient-92c97fd53b04dbf3Pharma Surgeen2026-07-03T00:00:00.000ZComparative Evaluation of Opioid-Free Versus Opioid-Based Anaesthesia in Patients Undergoing Spine Surgery: A Prospective Observational Studyhttps://www.pharmaradar360.com/article/occurrence-of-g-allele-at-rs1800976-of-abca1-gene-in-north-indian-population-har-a91059d5c0326467Pharma Surgeen2026-07-03T00:00:00.000ZOccurrence of G allele at rs1800976 of ABCA1 gene in North Indian population (Haryana) confers increased susceptibility to atherosclerotic complications in diabetic individualshttps://www.pharmaradar360.com/article/study-and-comparison-of-lip-print-for-sex-determination-and-permanency-over-a-ti-7d9e8270d987cab0Pharma Surgeen2026-07-03T00:00:00.000ZStudy and Comparison of Lip Print for Sex Determination and Permanency over a time period employing Three Methods: Lipstick, Latent, and Digital Photography in North Bihar Populationhttps://www.pharmaradar360.com/article/association-between-patellar-and-femoral-bone-morphology-overweight-status-and-s-24ff0dd262579014Pharma Surgeen2026-07-03T00:00:00.000ZAssociation Between Patellar and Femoral Bone Morphology, Overweight Status, and Sports Participation in Early Adolescentshttps://www.pharmaradar360.com/article/endoscopic-techniques-for-re-establishing-cerebrospinal-fluid-circulation-in-ven-8a1881eaaa48fdc3Pharma Surgeen2026-07-03T00:00:00.000ZEndoscopic Techniques for Re-establishing Cerebrospinal Fluid Circulation in Ventricular Tumorshttps://www.pharmaradar360.com/article/development-and-optimization-of-aprepitant-medicated-chocolates-by-box-behnken-e-b1619fe4a8cf5485Pharma Surgeen2026-07-03T00:00:00.000ZDEVELOPMENT AND OPTIMIZATION OF APREPITANT MEDICATED CHOCOLATES BY BOX–BEHNKEN EXPERIMENTAL DESIGNhttps://www.pharmaradar360.com/article/in-vitro-antidiabetic-activity-of-ethanolic-extract-of-parmotrema-perlatum-and-q-25e7a5aa06ea4beePharma Surgeen2026-07-03T00:00:00.000ZIN VITRO ANTIDIABETIC ACTIVITY OF ETHANOLIC EXTRACT OF PARMOTREMA PERLATUM AND QUANTITATIVE ESTIMATION OF QUERCETIN BY HPTLChttps://www.pharmaradar360.com/article/adonertinib-fhnd9041-versus-afatinib-as-first-line-treatment-for-advanced-non-sm-7fe81aa059ee053ePharma Surgeen2026-07-03T00:00:00.000ZAdonertinib (FHND9041) versus Afatinib as First-line Treatment for Advanced Non-small-cell Lung Cancer with EGFR Sensitive Mutation (FHND9041-Ⅲ-01): A Multi-centre, Open-label, Randomised Phase 3 Trialhttps://www.pharmaradar360.com/article/penicillin-clavulanate-susceptibility-in-clinical-mrsa-bloodstream-infection-str-a841db3513bf84bePharma Surgeen2026-07-03T00:00:00.000ZPenicillin-clavulanate susceptibility in clinical MRSA bloodstream infection strains from the CAMERA2 trialhttps://www.pharmaradar360.com/article/prospective-clinical-evaluation-of-a-fully-automated-ai-guided-echocardiographic-eaa667d85d402dcePharma Surgeen2026-07-03T00:00:00.000ZProspective Clinical Evaluation of a Fully Automated AI- Guided Echocardiographic Workflowhttps://www.pharmaradar360.com/article/effect-of-low-level-laser-therapy-on-healing-after-sinus-floor-augmentation-usin-30b217ece8906df9Pharma Surgeen2026-07-03T00:00:00.000ZEffect of low-level laser therapy on healing after sinus floor augmentation using allograft and xenograft bone materialshttps://www.pharmaradar360.com/article/steroid-induced-dermatitis-features-of-pathogenesis-and-treatment-challenges-00c6bd23e79e3f29Pharma Surgeen2026-07-03T00:00:00.000ZSteroid-induced dermatitis: features of pathogenesis and treatment challengeshttps://www.pharmaradar360.com/article/analysis-of-epidemiological-tendencies-of-syphilitic-infection-in-the-current-ge-4739c50768aa1eccPharma Surgeen2026-07-03T00:00:00.000ZAnalysis of epidemiological tendencies of syphilitic infection in the current geopolitical realities in the Russian Federationhttps://www.pharmaradar360.com/article/telomerase-as-a-therapeutic-bullseye-advances-in-cancer-treatment-and-clinical-t-bb3b021c47eb4407Pharma Surgeen2026-07-03T00:00:00.000ZTelomerase as a therapeutic Bullseye: advances in cancer treatment and clinical trialshttps://www.pharmaradar360.com/article/scaling-up-community-based-non-communicable-disease-research-into-practice-in-po-7055a0ea8f5bd413Pharma Surgeen2026-07-03T00:00:00.000ZScaling up community-based non-communicable disease research into practice in Pokhara Metropolitan City of Nepal (SCALE-NCD) trial: study protocol for a cluster-randomized controlled trialhttps://www.pharmaradar360.com/article/implementation-coverage-and-impact-of-a-programmatic-mass-drug-administration-ca-1d498b878896fdcbPharma Surgeen2026-07-03T00:00:00.000ZImplementation, coverage and impact of a programmatic mass drug administration campaign for malaria in southern Mozambiquehttps://www.pharmaradar360.com/article/low-psma-hormone-sensitive-prostate-cancer-a-distinct-clinical-and-molecular-sta-b9c4d2af01b97d1ePharma Surgeen2026-07-03T00:00:00.000ZLow-PSMA hormone-sensitive prostate cancer: a distinct clinical and molecular statehttps://www.pharmaradar360.com/article/emerging-trends-in-smart-wearable-technologies-across-medical-and-lifestyle-doma-febf456a00cc9810Pharma Surgeen2026-07-03T00:00:00.000ZEmerging Trends in Smart Wearable Technologies Across Medical and Lifestyle Domains: Implications for Personalized Healthcarehttps://www.pharmaradar360.com/article/performance-evaluation-of-a-canine-c-reactive-protein-flow-immunosensor-measurem-a2c970cf3fa12911Pharma Surgeen2026-07-03T00:00:00.000ZPerformance evaluation of a canine C-reactive protein flow-immunosensor measurement system for clinical applicationhttps://www.pharmaradar360.com/article/clinical-psychological-characteristics-and-clonazepam-outcomes-in-burning-mouth-c7eac22f77675952Pharma Surgeen2026-07-03T00:00:00.000ZClinical–Psychological Characteristics and Clonazepam Outcomes in Burning Mouth Syndrome: A Systematic Review Based on the <scp>SWiM</scp> Approachhttps://www.pharmaradar360.com/article/effectiveness-of-augmented-reality-guided-interdental-brushing-instruction-compa-e2a1bb5ac9f0fee3Pharma Surgeen2026-07-03T00:00:00.000ZEffectiveness of Augmented Reality‐Guided Interdental Brushing Instruction Compared With Conventional Methods: A Three‐Arm Randomized Controlled Trialhttps://www.pharmaradar360.com/article/the-emerging-role-of-pirnas-in-periodontal-and-orthodontic-tissue-dynamics-biolo-442ff0698ca0e97dPharma Surgeen2026-07-03T00:00:00.000ZThe emerging role of piRNAs in periodontal and orthodontic tissue dynamics: Biological insights and clinical perspectives—A reviewhttps://www.pharmaradar360.com/article/hudi-enteric-coated-capsule-and-its-active-constituent-polydatin-suppress-th1-th-124afe92b3995786Pharma Surgeen2026-07-03T00:00:00.000ZHudi enteric-coated capsule and its active constituent polydatin suppress Th1/Th17-mediated intestinal inflammation by modulating the KEAP1-NFE2L2 signaling pathwayhttps://www.pharmaradar360.com/article/multidrug-resistant-i-pseudomonas-aeruginosa-i-in-jordan-epidemiology-trends-det-4f22932ac502d899Pharma Surgeen2026-07-03T00:00:00.000ZMultidrug-resistant <i>Pseudomonas aeruginosa</i> in Jordan: epidemiology, trends, determinants, and clinical outcomeshttps://www.pharmaradar360.com/article/forward-genetics-reveals-microsporidian-drug-targets-and-recombination-based-res-26adadeb66522ba7Pharma Surgeen2026-07-03T00:00:00.000ZForward genetics reveals microsporidian drug targets and recombination-based resistancehttps://www.pharmaradar360.com/article/metabolic-transcriptomic-subtyping-defines-distinct-immunogenomic-and-clinical-l-b53f552d72d33ebePharma Surgeen2026-07-03T00:00:00.000ZMetabolic transcriptomic subtyping defines distinct immunogenomic and clinical landscapes in non–small cell lung cancerhttps://www.pharmaradar360.com/article/specific-learning-disabilities-in-africa-a-narrative-review-of-underdiagnosis-di-7ccf7a30be979293Pharma Surgeen2026-07-03T00:00:00.000ZSpecific Learning Disabilities in Africa: A Narrative Review of Underdiagnosis, Diagnostic Barriers, and Gaps in Carehttps://www.pharmaradar360.com/article/effect-of-shenling-baizhu-powder-on-diarrhea-induced-by-fatigue-and-high-fat-die-dcdb72553d8d1cd6Pharma Surgeen2026-07-03T00:00:00.000ZEffect of Shenling Baizhu powder on diarrhea induced by fatigue and high-fat diet: association with gut microbiota and bile acid metabolismhttps://www.pharmaradar360.com/article/clinical-characteristics-of-angioid-streaks-in-japanese-patients-0385d5a6b79b2463Pharma Surgeen2026-07-03T00:00:00.000ZClinical characteristics of angioid streaks in Japanese patientshttps://www.pharmaradar360.com/article/correction-clinical-practice-guideline-for-anterior-segment-dysgenesis-315b4e713f4296ecPharma Surgeen2026-07-03T00:00:00.000ZCorrection: Clinical practice guideline for anterior segment dysgenesishttps://www.pharmaradar360.com/article/fact-check-target-baby-wipes-recalled-for-bacteria-risk-but-fda-didn-t-upgrade-n-8135f52811472832Pharma Surgeen2026-07-02T23:44:00.000ZFact Check: Target baby wipes recalled for bacteria risk, but FDA didn't 'upgrade' noticehttps://www.pharmaradar360.com/article/keep-britain-working-review-update-march-2026-8a0d4bc16c467ec8Pharma Surgeen2026-07-02T23:01:01.000ZKeep Britain Working review update: March 2026https://www.pharmaradar360.com/article/keep-britain-working-review-update-june-2026-bac12cbf358b7e62Pharma Surgeen2026-07-02T23:01:01.000ZKeep Britain Working review update: June 2026https://www.pharmaradar360.com/article/keep-britain-working-20e801e2a2496745Pharma Surgeen2026-07-02T23:01:01.000ZKeep Britain Workinghttps://www.pharmaradar360.com/article/veraxa-biotech-stock-in-focus-as-lead-cancer-program-reaches-development-milesto-0bea9fba6112a47aPharma Surgeen2026-07-02T22:40:48.000ZVERAXA Biotech Stock in Focus as Lead Cancer Program Reaches Development Milestonehttps://www.pharmaradar360.com/article/united-kingdom-pharmaceutical-lab-equipment-market-analysis-forecast-size-trends-78624145878013e1Pharma Surgeen2026-07-02T22:39:53.000ZUnited Kingdom Pharmaceutical Lab Equipment - Market Analysis, Forecast, Size, Trends and Insightshttps://www.pharmaradar360.com/article/fda-probes-anesthesia-linked-neurological-complications-in-some-patients-of-vene-8e706326f4ff15b2Pharma Surgeen2026-07-02T21:49:44.000ZFDA probes anesthesia-linked neurological complications in some patients of Venezuelan ancestryhttps://www.pharmaradar360.com/article/fda-investigates-sevoflurane-safety-amid-neurologic-concerns-b421d439fc86f3baPharma Surgeen2026-07-02T21:46:50.000ZFDA Investigates Sevoflurane Safety Amid Neurologic Concernshttps://www.pharmaradar360.com/article/procesos-de-compras-ucp-a0fc49b8b545dbcbPharma Surgeen2026-07-02T21:44:30.000ZProcesos de Compras UCPhttps://www.pharmaradar360.com/article/fda-to-hire-2-200-staffers-as-it-narrows-search-for-commissioner-names-produce-s-e9c5fbc2ac3786b6Pharma Surgeen2026-07-02T21:43:03.000ZFDA to Hire 2,200 Staffers as it Narrows Search for Commissioner, Names Produce Safety Directorhttps://www.pharmaradar360.com/article/nhs-patients-get-faster-access-to-medicines-under-new-pilots-c28f61a63886cbe7Pharma Surgeen2026-07-02T21:31:00.000ZNHS patients get faster access to medicines under new pilotshttps://www.pharmaradar360.com/article/fda-recalls-malfunctioning-pacemakers-after-injuries-and-deaths-what-patients-sh-42597ad4caae77c6Pharma Surgeen2026-07-02T21:21:25.000ZFDA recalls malfunctioning pacemakers after injuries and deaths. What patients should do now.https://www.pharmaradar360.com/article/lrmr-shares-hold-steady-as-wall-street-optimism-offsets-drug-safety-concerns-879bf6faf5236477Pharma Surgeen2026-07-02T20:32:52.000ZLRMR Shares Hold Steady As Wall Street Optimism Offsets Drug Safety Concernshttps://www.pharmaradar360.com/article/bay-area-biotech-giant-to-lay-off-103-employees-0c33e67101782ddePharma Surgeen2026-07-02T20:14:40.000ZBay Area biotech giant to lay off 103 employeeshttps://www.pharmaradar360.com/article/drug-alerts-and-statements-65b7066201a76f64Pharma Surgeen2026-07-02T20:07:22.000ZDrug Alerts and Statementshttps://www.pharmaradar360.com/article/is-agomab-therapeutics-nv-agmb-stock-a-biotech-opportunity-with-targeted-tissue-87be06d69e7ebe2ePharma Surgeen2026-07-02T20:06:30.000ZIs AgomAB Therapeutics NV (AGMB) Stock a Biotech Opportunity With Targeted Tissue Therapy Potential?https://www.pharmaradar360.com/article/inovio-pharmaceuticals-nasdaq-ino-files-300m-shelf-registration-notes-bla-pdufa-16ea7d945a733ef8Pharma Surgeen2026-07-02T20:03:28.000ZInovio Pharmaceuticals (NASDAQ: INO) files $300M shelf registration, notes BLA PDUFAhttps://www.pharmaradar360.com/article/is-septerna-inc-sepn-stock-a-biotech-opportunity-with-a-potential-first-in-class-b6b922f75184a5b5Pharma Surgeen2026-07-02T19:58:24.000ZIs Septerna, Inc. (SEPN) Stock a Biotech Opportunity With a Potential First-in-Class Hypoparathyroidism Treatment?https://www.pharmaradar360.com/article/is-mineralys-therapeutics-inc-mlys-stock-a-biotech-opportunity-with-lorundrostat-04412f5afe702a6dPharma Surgeen2026-07-02T19:58:14.000ZIs Mineralys Therapeutics, Inc. (MLYS) Stock a Biotech Opportunity With Lorundrostat’s Expanding Cardiovascular Potential?https://www.pharmaradar360.com/article/fda-names-donna-garren-director-of-produce-safety-61280b383fcf9b30Pharma Surgeen2026-07-02T19:53:00.000ZFDA Names Donna Garren Director of Produce Safetyhttps://www.pharmaradar360.com/article/biotech-firms-name-new-ceos-leadership-after-bio-3df6eee16416d39aPharma Surgeen2026-07-02T19:25:34.000ZBiotech firms name new CEOs, leadership after BIOhttps://www.pharmaradar360.com/article/alibaba-to-pay-600-million-to-u-s-for-illegal-pharmaceutical-sales-9ce71c8902f406a6Pharma Surgeen2026-07-02T19:16:37.000ZAlibaba to pay $600 million to U.S. for illegal pharmaceutical saleshttps://www.pharmaradar360.com/article/more-than-944-000-bottles-of-heart-and-kidney-meds-recalled-nationwide-95d5f2f5666a0cddPharma Surgeen2026-07-02T19:09:19.000ZMore than 944,000 bottles of heart and kidney meds recalled nationwidehttps://www.pharmaradar360.com/article/biotech-gives-sbio-its-best-month-since-2023-046d593c63bd2181Pharma Surgeen2026-07-02T18:06:29.000ZBiotech Gives SBIO Its Best Month Since 2023https://www.pharmaradar360.com/article/hantavirus-outbreak-linked-to-cruise-ship-travel-multi-locations-d9719395b156cadfPharma Surgeen2026-07-02T18:00:00.000ZHantavirus outbreak linked to cruise ship travel, Multi-locationshttps://www.pharmaradar360.com/article/abbvie-inc-stock-abbv-moved-up-by-3-44-on-jul-2-drivers-behind-the-movement-95b7567ae319d40fPharma Surgeen2026-07-02T17:15:29.000ZAbbVie Inc Stock (ABBV) Moved Up by 3.44% on Jul 2: Drivers Behind the Movementhttps://www.pharmaradar360.com/article/the-week-s-10-biggest-funding-rounds-ai-energy-and-biotech-lead-the-way-7ff0f6cb2755b326Pharma Surgeen2026-07-02T17:12:50.000ZThe Week’s 10 Biggest Funding Rounds: AI, Energy And Biotech Lead The Wayhttps://www.pharmaradar360.com/article/the-charts-on-this-biotech-stock-look-attractive-says-jay-woods-97625b858e597f43Pharma Surgeen2026-07-02T17:00:01.000ZThe charts on this biotech stock look attractive, says Jay Woodshttps://www.pharmaradar360.com/article/medical-services-name-tests-for-colon-cancer-natera-stock-hits-a-high-2b784ad2310d29c9Pharma Surgeen2026-07-02T16:56:35.000ZMedical services name tests for colon cancer. Natera stock hits a highhttps://www.pharmaradar360.com/article/molecular-cancer-therapeutics-improving-immune-checkpoint-blockade-efficacy-in-m-e4eb0f79e79b2424Pharma Surgeen2026-07-02T16:23:19.000ZMolecular Cancer Therapeutics: Improving Immune Checkpoint Blockade Efficacy in Melanoma Brain Metastases through Myddosomal inhibition with Emavusertibhttps://www.pharmaradar360.com/article/veraxa-biotech-collaborates-with-atum-on-cell-line-development-to-advance-lead-b-d66d0fbf266be21fPharma Surgeen2026-07-02T16:18:27.000ZVERAXA Biotech Collaborates with ATUM on Cell Line Development to Advance Lead BiTAC®-TCE Programhttps://www.pharmaradar360.com/article/on-behalf-of-respighi-bidco-s-p-a-reopening-of-the-review-period-c13fb2a6ff8211a5Pharma Surgeen2026-07-02T16:13:28.000ZOn behalf of Respighi BidCo S.p.A – Reopening of the review periodhttps://www.pharmaradar360.com/article/mexico-city-unveils-us-125-million-biotech-investment-initiative-a91f714518196e24Pharma Surgeen2026-07-02T16:12:44.000ZMexico City Unveils US$125 Million Biotech Investment Initiativehttps://www.pharmaradar360.com/article/tenax-therapeutics-announces-late-breaking-presentation-of-level-clinical-trial-24938326737a03ddPharma Surgeen2026-07-02T16:09:49.000ZTenax Therapeutics Announces Late-Breaking Presentation of LEVEL Clinical Trial Data at ESC Congress 2026https://www.pharmaradar360.com/article/nhs-injury-costs-recovery-scheme-april-2026-to-march-2027-8ea107a36a0e2402Pharma Surgeen2026-07-02T16:01:03.000ZNHS injury costs recovery scheme: April 2026 to March 2027https://www.pharmaradar360.com/article/medicines-apply-for-a-variation-to-your-marketing-authorisation-e18dc448dade6b1fPharma Surgeen2026-07-02T15:58:54.000ZMedicines: apply for a variation to your marketing authorisationhttps://www.pharmaradar360.com/article/roche-kras-drug-succeeds-in-head-to-head-lung-cancer-study-5ed233fc265181bePharma Surgeen2026-07-02T15:58:12.000ZRoche KRAS drug succeeds in head-to-head lung cancer studyhttps://www.pharmaradar360.com/article/dipanjan-pan-phd-on-early-stage-tear-biosensor-research-closed-loop-drug-deliver-c0fca08c38295c14Pharma Surgeen2026-07-02T15:55:01.000ZDipanjan Pan, PhD, on early-stage tear biosensor research, closed-loop drug delivery, and the road to FDA clearancehttps://www.pharmaradar360.com/article/glenmark-advances-phase-3-trial-of-her2-targeted-adc-for-platinum-resistant-ovar-0838c56db4545887Pharma Surgeen2026-07-02T15:09:09.000ZGlenmark advances Phase 3 trial of HER2-targeted ADC for platinum-resistant ovarian cancerhttps://www.pharmaradar360.com/article/nearly-1-million-bottles-of-a-heart-failure-drug-were-just-recalled-check-your-m-3d53f997331a7c60Pharma Surgeen2026-07-02T15:00:11.000ZNearly 1 Million Bottles of a Heart Failure Drug Were Just Recalled — Check Your Medicine Cabinethttps://www.pharmaradar360.com/article/work-related-quality-of-life-of-the-adult-social-care-workforce-in-england-in-20-5dda61eaa33e2f01Pharma Surgeen2026-07-02T15:00:01.000ZWork-related quality of life of the adult social care workforce in England in 2025https://www.pharmaradar360.com/article/biotech-s-china-problem-an-issue-of-national-security-or-economic-value-for-the-28a1f5fb9a7d2451Pharma Surgeen2026-07-02T14:58:43.000ZBiotech’s China problem: An issue of national security or economic value for the US?https://www.pharmaradar360.com/article/how-pitt-s-bioforge-kept-a-new-york-based-biotech-startup-s-presence-in-pittsbur-630b2601c518d62bPharma Surgeen2026-07-02T14:56:04.000ZHow Pitt’s BioForge kept a New York-based biotech startup’s presence in Pittsburghhttps://www.pharmaradar360.com/article/guidance-medicines-that-you-cannot-export-from-the-uk-or-hoard-4663215c934b740cPharma Surgeen2026-07-02T14:46:34.000ZGuidance: Medicines that you cannot export from the UK or hoardhttps://www.pharmaradar360.com/article/west-pharmaceutical-services-stock-surges-13-with-a-9-day-winning-spree-f3207c4d07050271Pharma Surgeen2026-07-02T14:43:01.000ZWest Pharmaceutical Services Stock Surges 13%, With A 9-Day Winning Spreehttps://www.pharmaradar360.com/article/cmps-stock-rises-23-pre-market-as-compass-achieves-primary-endpoint-in-phase-3-t-4191aa06fc271c3ePharma Surgeen2026-07-02T14:34:22.000ZCMPS Stock Rises 23% Pre-Market As Compass Achieves Primary Endpoint In Phase 3 Treatment-Resistant Depression Trialhttps://www.pharmaradar360.com/article/outbreaks-under-monitoring-in-2026-eb6ae222898106b1Pharma Surgeen2026-07-02T14:30:05.000ZOutbreaks under monitoring in 2026https://www.pharmaradar360.com/article/ipf-biotech-celea-gets-180m-to-follow-paths-of-puretech-s-karuna-seaport-0299ee434050befbPharma Surgeen2026-07-02T14:28:00.000ZIPF biotech Celea gets $180M to follow paths of PureTech’s Karuna, Seaporthttps://www.pharmaradar360.com/article/roche-drug-sets-new-standard-for-kras-driven-lung-cancer-51ea80ca27e7501dPharma Surgeen2026-07-02T14:18:08.000ZRoche drug sets new standard for KRAS-driven lung cancerhttps://www.pharmaradar360.com/article/tenax-therapeutics-to-present-phase-3-level-trial-results-for-levosimendan-in-ph-755044c6e88c8e94Pharma Surgeen2026-07-02T14:07:00.000ZTenax Therapeutics to Present Phase 3 LEVEL Trial Results for Levosimendan in PH-HFpEF at ESC Congress 2026https://www.pharmaradar360.com/article/what-a-brooklyn-bodega-reveals-about-the-craze-for-an-experimental-weight-loss-d-81d53e494ee66a8aPharma Surgeen2026-07-02T14:00:00.000ZWhat a Brooklyn bodega reveals about the craze for an experimental weight-loss drughttps://www.pharmaradar360.com/article/trinity-biotech-reports-positive-clinical-findings-for-next-gen-cgm-e21082a8a77c5d31Pharma Surgeen2026-07-02T13:54:20.000ZTrinity Biotech reports positive clinical findings for next-gen CGMhttps://www.pharmaradar360.com/article/fda-widens-vertex-s-casgevy-use-for-paediatric-patients-f3a1e57292a3844aPharma Surgeen2026-07-02T13:51:55.000ZFDA widens Vertex’s Casgevy use for paediatric patientshttps://www.pharmaradar360.com/article/trinity-biotech-reports-positive-clinical-findings-for-next-gen-cgm-27b9ee0836a21a70Pharma Surgeen2026-07-02T13:49:05.000ZTrinity Biotech reports positive clinical findings for next-gen CGMhttps://www.pharmaradar360.com/article/ipsen-bolsters-rare-disease-pipeline-in-700m-memo-takeover-3707c39fe6078bb2Pharma Surgeen2026-07-02T13:41:15.000ZIpsen bolsters rare disease pipeline in €700m Memo takeoverhttps://www.pharmaradar360.com/article/vrxa-stock-price-news-analysis-2b09819439ca80fePharma Surgeen2026-07-02T13:38:49.000ZVRXA Stock Price, News & Analysishttps://www.pharmaradar360.com/article/7-fda-decisions-to-watch-for-in-q3-d051530733736f17Pharma Surgeen2026-07-02T13:38:40.000Z7 FDA decisions to watch for in Q3https://www.pharmaradar360.com/article/why-animal-models-still-matter-in-drug-development-ad7ac4ea927c6fafPharma Surgeen2026-07-02T13:33:41.000ZWhy animal models still matter in drug developmenthttps://www.pharmaradar360.com/article/cordis-project-data-driven-excellence-in-training-of-epidemiological-clinical-te-c9e214e9798669b7Pharma Surgeen2026-07-02T13:32:04.000ZCORDIS project: Data driven Excellence in Training of Epidemiological, Clinical, Technological and Innovative Virus Expertshttps://www.pharmaradar360.com/article/cordis-project-vaccinologists-for-europe-training-network-for-developing-next-ge-ac1c53810b8b50a7Pharma Surgeen2026-07-02T13:32:04.000ZCORDIS project: Vaccinologists for Europe: Training network for developing next generation vaccines against mucosal pathogenshttps://www.pharmaradar360.com/article/cordis-project-resolving-the-signal-to-noise-ratio-challenge-for-precision-liqui-319bd6ed5addd127Pharma Surgeen2026-07-02T13:32:04.000ZCORDIS project: Resolving the signal-to-noise ratio challenge for precision liquid biopsy and early solid tumor surveillancehttps://www.pharmaradar360.com/article/cordis-project-a-next-generation-pcr-tool-for-rapid-and-early-diagnosis-of-sepsi-b7b3764cc49d76ecPharma Surgeen2026-07-02T13:32:04.000ZCORDIS project: A next-generation PCR tool for rapid and early diagnosis of sepsis aetiologyhttps://www.pharmaradar360.com/article/cordis-project-perturbation-based-phosphoproteomics-to-study-drug-response-heter-d5be0388e275203bPharma Surgeen2026-07-02T13:32:03.000ZCORDIS project: Perturbation-based Phosphoproteomics to Study Drug Response Heterogeneityhttps://www.pharmaradar360.com/article/cordis-project-precision-oncology-platform-for-personalised-cannabinoid-based-ca-503641e8fb7b1b1bPharma Surgeen2026-07-02T13:32:02.000ZCORDIS project: Precision oncology platform for personalised cannabinoid-based cancer therapieshttps://www.pharmaradar360.com/article/an-extra-229-000-deaths-is-that-the-cost-of-us-uk-drugs-deal-ded292d3a9c13fbePharma Surgeen2026-07-02T13:19:31.000ZAn extra 229,000 deaths: Is that the cost of US-UK drugs deal?https://www.pharmaradar360.com/article/biotech-pre-market-pulse-limn-tenx-eltx-swing-big-301c616a52c84bbaPharma Surgeen2026-07-02T13:17:00.000ZBiotech Pre-Market Pulse: LIMN, TENX, ELTX Swing Bighttps://www.pharmaradar360.com/article/the-rwe-communication-gap-that-s-costing-manufacturers-formulary-access-47df01030fbf3832Pharma Surgeen2026-07-02T13:08:16.000ZThe RWE Communication Gap That's Costing Manufacturers Formulary Accesshttps://www.pharmaradar360.com/article/trilogy-laboratories-acquires-yns-cosmeceuticals-bringing-pharmaceutical-experti-4248002ca2eba640Pharma Surgeen2026-07-02T13:02:00.000ZTrilogy Laboratories Acquires YNS Cosmeceuticals, Bringing Pharmaceutical Expertise and Physician Leadership to a Trusted Skincare Brandhttps://www.pharmaradar360.com/article/biotech-investor-pumps-the-brakes-on-ai-drug-discovery-88d76ca530f3fd4cPharma Surgeen2026-07-02T13:00:14.000ZBiotech Investor Pumps the Brakes on AI Drug Discoveryhttps://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-2025-to-2026-695ba9f5e6b7fd05Pharma Surgeen2026-07-02T13:00:02.000ZWeekly all-cause mortality surveillance: 2025 to 2026https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-reports-2025-to-2026-season-d6b3a2494c57cfa7Pharma Surgeen2026-07-02T13:00:02.000ZNational flu and COVID-19 surveillance reports: 2025 to 2026 seasonhttps://www.pharmaradar360.com/article/syndromic-surveillance-weekly-summaries-for-2026-45747e3878253defPharma Surgeen2026-07-02T13:00:02.000ZSyndromic surveillance: weekly summaries for 2026https://www.pharmaradar360.com/article/remote-health-advice-weekly-bulletins-for-2026-0b8fbceac342c05cPharma Surgeen2026-07-02T13:00:02.000ZRemote health advice: weekly bulletins for 2026https://www.pharmaradar360.com/article/national-ambulance-syndromic-surveillance-weekly-bulletins-2026-6dee157afd1fba75Pharma Surgeen2026-07-02T13:00:02.000ZNational ambulance syndromic surveillance: weekly bulletins 2026https://www.pharmaradar360.com/article/gp-out-of-hours-syndromic-surveillance-weekly-bulletins-for-2026-f212a5a75078c06ePharma Surgeen2026-07-02T13:00:02.000ZGP out-of-hours syndromic surveillance: weekly bulletins for 2026https://www.pharmaradar360.com/article/gp-in-hours-weekly-bulletins-for-2026-dfebf391f225843dPharma Surgeen2026-07-02T13:00:02.000ZGP in-hours: weekly bulletins for 2026https://www.pharmaradar360.com/article/emergency-department-weekly-bulletins-for-2026-08abcdde2881ef86Pharma Surgeen2026-07-02T13:00:02.000ZEmergency department: weekly bulletins for 2026https://www.pharmaradar360.com/article/what-s-driving-direct-to-patient-model-adoption-across-pharma-c5fcc588c06173f1Pharma Surgeen2026-07-02T13:00:00.000ZWhat's Driving Direct-to-Patient Model Adoption Across Pharma?https://www.pharmaradar360.com/article/jyong-biotech-presents-drug-candidate-at-bio-2026-convention-8c048da8a228fa51Pharma Surgeen2026-07-02T12:52:36.000ZJyong Biotech presents drug candidate at BIO 2026 conventionhttps://www.pharmaradar360.com/article/what-to-expect-from-west-pharmaceutical-services-q2-2026-earnings-report-c159bdad4417a615Pharma Surgeen2026-07-02T12:34:13.000ZWhat to Expect From West Pharmaceutical Services' Q2 2026 Earnings Reporthttps://www.pharmaradar360.com/article/fosun-pays-32m-to-join-lilly-and-novartis-in-fiercely-competitive-psoriasis-mark-027346c2c56b5e41Pharma Surgeen2026-07-02T12:30:00.000ZFosun pays $32M to join Lilly and Novartis in fiercely competitive psoriasis markethttps://www.pharmaradar360.com/article/roche-orchestrates-phase-3-kras-lung-cancer-win-over-amgen-bms-25eeaa042437e631Pharma Surgeen2026-07-02T12:30:00.000ZRoche orchestrates phase 3 KRAS lung cancer win over Amgen, BMShttps://www.pharmaradar360.com/article/revolution-medicines-presents-phase-1-2-clinical-data-for-zoldonrasib-combinatio-d43ae879b40afffePharma Surgeen2026-07-02T12:22:03.000ZRevolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026https://www.pharmaradar360.com/article/spdr-health-care-etf-tops-ishares-biotech-in-long-term-returns-7a704a643a698de6Pharma Surgeen2026-07-02T12:15:01.000ZSPDR Health Care ETF Tops iShares Biotech in Long-Term Returnshttps://www.pharmaradar360.com/article/spdr-health-care-etf-tops-ishares-biotech-in-long-term-returns-9c0e522ff208c41bPharma Surgeen2026-07-02T12:05:01.000ZSPDR Health Care ETF Tops iShares Biotech in Long-Term Returnshttps://www.pharmaradar360.com/article/nkgen-biotech-to-present-at-the-2026-biochina-global-forum-1ab687e3667e6c87Pharma Surgeen2026-07-02T12:05:00.000ZNKGen Biotech to Present at the 2026 BIOCHINA Global Forumhttps://www.pharmaradar360.com/article/late-breaking-esc-2026-spot-for-tenax-tenx-phase-3-level-trial-data-6e67a4c70232dc68Pharma Surgeen2026-07-02T12:01:12.000ZLate-breaking ESC 2026 spot for Tenax (TENX) Phase 3 LEVEL trial datahttps://www.pharmaradar360.com/article/nephromax-high-pressure-nephrostomy-balloon-catheter-f4cb332572d33b6bPharma Surgeen2026-07-02T12:00:00.000ZNephroMax High Pressure Nephrostomy Balloon Catheterhttps://www.pharmaradar360.com/article/lifecodes-lsa-class-ii-dae6fd059e7f6377Pharma Surgeen2026-07-02T12:00:00.000ZLIFECODES LSA Class IIhttps://www.pharmaradar360.com/article/glidesheath-slender-introducer-sheath-8a7af6818d0a8081Pharma Surgeen2026-07-02T12:00:00.000ZGlidesheath Slender® Introducer Sheathhttps://www.pharmaradar360.com/article/fludeoxyglucose-18f-injection-cracket-vial-91714d4a458d5007Pharma Surgeen2026-07-02T12:00:00.000ZFludeoxyglucose (18F) Injection; Cracket vialhttps://www.pharmaradar360.com/article/airseal-access-port-with-blunt-obturator-and-airseal-access-port-with-optical-ob-11dc73defafdedb1Pharma Surgeen2026-07-02T12:00:00.000ZAirSeal Access Port With Blunt Obturator and AirSeal Access Port With Optical Obturatorhttps://www.pharmaradar360.com/article/jyong-biotech-pitched-its-plant-based-bph-drug-to-pharma-partners-at-bio-2026-31a41365b835c2ffPharma Surgeen2026-07-02T12:00:00.000ZJyong Biotech pitched its plant-based BPH drug to pharma partners at BIO 2026https://www.pharmaradar360.com/article/revolution-medicines-shows-82-response-in-pancreatic-cancer-combo-trial-d093cdcff944b4a5Pharma Surgeen2026-07-02T12:00:00.000ZRevolution Medicines shows 82% response in pancreatic cancer combo trialhttps://www.pharmaradar360.com/article/jyong-biotech-showcases-botanical-drug-portfolio-at-bio-2026-international-conve-1ae151d3ff80d797Pharma Surgeen2026-07-02T12:00:00.000ZJyong Biotech Showcases Botanical Drug Portfolio at BIO 2026 International Conventionhttps://www.pharmaradar360.com/article/vivani-announces-entry-into-merger-agreement-between-wholly-owned-subsidiary-cor-02abbcb2b62a749bPharma Surgeen2026-07-02T12:00:00.000ZVivani Announces Entry into Merger Agreement Between Wholly Owned Subsidiary Cortigent, Inc. and Nasdaq-listed ClearOne, Inc.https://www.pharmaradar360.com/article/pharmaceutical-technology-d80d4b754683513dPharma Surgeen2026-07-02T11:57:00.000ZPharmaceutical Technologyhttps://www.pharmaradar360.com/article/podcast-hlth-europe-and-bio-key-trends-rundown-337303b01579b413Pharma Surgeen2026-07-02T11:48:45.000ZPodcast: HLTH Europe and BIO key trends rundownhttps://www.pharmaradar360.com/article/telix-advances-phase-3-prostate-trial-after-fda-alignment-32e3a55268188402Pharma Surgeen2026-07-02T11:47:00.000ZTelix advances Phase 3 prostate trial after FDA alignmenthttps://www.pharmaradar360.com/article/tenax-therapeutics-to-present-phase-3-trial-results-at-esc-90bbbe23ba6b6f45Pharma Surgeen2026-07-02T11:27:15.000ZTenax Therapeutics to present Phase 3 trial results at ESChttps://www.pharmaradar360.com/article/kane-biotech-announces-results-of-annual-and-special-meeting-of-shareholders-5dc2419e4467d457Pharma Surgeen2026-07-02T11:25:00.000ZKane Biotech Announces Results of Annual and Special Meeting of Shareholdershttps://www.pharmaradar360.com/article/wall-street-thinks-this-biotech-stock-can-soar-45-here-s-why-analysts-are-right-868612ab5086bdedPharma Surgeen2026-07-02T11:06:48.000ZWall Street Thinks This Biotech Stock Can Soar 45%. Here's Why Analysts Are Right.https://www.pharmaradar360.com/article/thermo-fisher-to-back-arcturus-nasdaq-arct-arct-032-phase-3-and-manufacturing-cc37e9d7b209c515Pharma Surgeen2026-07-02T11:06:24.000ZThermo Fisher to back Arcturus (NASDAQ: ARCT) ARCT-032 Phase 3 and manufacturinghttps://www.pharmaradar360.com/article/china-ai-drug-design-deals-swell-as-us-scrutiny-mounts-25460db6c16037caPharma Surgeen2026-07-02T11:00:10.000ZChina AI drug-design deals swell as US scrutiny mountshttps://www.pharmaradar360.com/article/rare-and-imported-pathogens-laboratory-ripl-user-manual-9019c0801efa285ePharma Surgeen2026-07-02T11:00:01.000ZRare and Imported Pathogens Laboratory (RIPL): user manualhttps://www.pharmaradar360.com/article/veraxa-advances-lead-cancer-drug-toward-manufacturing-work-with-atum-e50939384e0a2961Pharma Surgeen2026-07-02T11:00:00.000ZVERAXA advances lead cancer drug toward manufacturing work with ATUMhttps://www.pharmaradar360.com/article/arcturus-taps-thermo-fisher-to-make-its-cystic-fibrosis-therapy-d47dedd36ac9c659Pharma Surgeen2026-07-02T11:00:00.000ZArcturus taps Thermo Fisher to make its cystic fibrosis therapyhttps://www.pharmaradar360.com/article/tenax-to-present-level-trial-data-at-esc-congress-before-august-results-41f88e0d13e34b76Pharma Surgeen2026-07-02T11:00:00.000ZTenax to present LEVEL trial data at ESC Congress before August resultshttps://www.pharmaradar360.com/article/tenax-therapeutics-announces-late-breaking-presentation-of-level-clinical-trial-5412b80db22ab923Pharma Surgeen2026-07-02T11:00:00.000ZTenax Therapeutics Announces Late-Breaking Presentation of LEVEL Clinical Trial Data at ESC Congress 2026https://www.pharmaradar360.com/article/arcturus-therapeutics-announces-strategic-collaboration-with-thermo-fisher-scien-648700ed5c0eecbdPharma Surgeen2026-07-02T11:00:00.000ZArcturus Therapeutics Announces Strategic Collaboration with Thermo Fisher Scientific to Advance ARCT-032 for Cystic Fibrosishttps://www.pharmaradar360.com/article/wall-street-thinks-this-biotech-stock-can-soar-45-here-s-why-analysts-are-right-0f052de59c1aa164Pharma Surgeen2026-07-02T10:53:43.000ZWall Street Thinks This Biotech Stock Can Soar 45%. Here's Why Analysts Are Right.https://www.pharmaradar360.com/article/wall-street-thinks-this-biotech-stock-can-soar-45-here-s-why-analysts-are-right-89deca2a7d2873a5Pharma Surgeen2026-07-02T10:53:00.000ZWall Street Thinks This Biotech Stock Can Soar 45%. Here's Why Analysts Are Right.https://www.pharmaradar360.com/article/cordis-project-initiatives-to-accelerate-the-translation-of-research-into-market-d0650c0d4bc76526Pharma Surgeen2026-07-02T10:49:19.000ZCORDIS project: Initiatives to Accelerate the Translation of Research into Market-Ready Surgical Implantable Medical Devices by Strengthening Regulatory Science and Improved Regulatory Competencies Among Researchershttps://www.pharmaradar360.com/article/cordis-project-mediq-index-local-clinical-ai-assistant-for-real-time-patient-sum-ba9a734a4980a109Pharma Surgeen2026-07-02T10:49:19.000ZCORDIS project: MEDIQ Index - Local Clinical AI assistant for Real-Time Patient Summarization and Queryhttps://www.pharmaradar360.com/article/analysis-50-cut-in-danish-pharma-production-could-cost-30-000-jobs-9d605be0cc93f389Pharma Surgeen2026-07-02T10:43:07.000ZAnalysis: 50% cut in Danish pharma production could cost 30,000 jobshttps://www.pharmaradar360.com/article/fda-approved-cannabis-why-schedule-3-means-operators-must-prepare-for-pharmaceut-5421ff5c3be320a8Pharma Surgeen2026-07-02T10:33:33.000ZFDA approved cannabis: Why Schedule 3 means operators must prepare for pharmaceutical-grade MMJ nowhttps://www.pharmaradar360.com/article/halfway-into-the-year-biotech-is-booming-4ad98a2294653004Pharma Surgeen2026-07-02T10:33:10.000ZHalfway into the year, biotech is boominghttps://www.pharmaradar360.com/article/adragos-and-towa-to-produce-1-5-billion-tablets-a-year-f7004863d35e1305Pharma Surgeen2026-07-02T10:32:25.000ZAdragos and Towa to Produce 1.5 Billion Tablets a Yearhttps://www.pharmaradar360.com/article/shanghai-fudan-zhangjiang-bio-pharmaceutical-subscribes-structured-deposit-produ-1313e3a1786dc08ePharma Surgeen2026-07-02T10:27:35.000ZShanghai Fudan-Zhangjiang Bio-Pharmaceutical Subscribes Structured Deposit Product With Amount Of RMB330 MLNhttps://www.pharmaradar360.com/article/astrazeneca-signs-cspc-china-deal-for-experimental-kidney-disease-drugs-44048240c14efde7Pharma Surgeen2026-07-02T10:17:43.000ZAstraZeneca signs CSPC China deal for experimental kidney disease drugshttps://www.pharmaradar360.com/article/us-launches-security-probe-into-five-pharma-giants-doing-clinical-trials-in-chin-bf01c28ba3004ff0Pharma Surgeen2026-07-02T10:08:57.000ZUS launches security probe into five pharma giants doing clinical trials in Chinahttps://www.pharmaradar360.com/article/realistic-timelines-for-pharma-manufacturing-reshoring-4499d498dc4fc84fPharma Surgeen2026-07-02T10:07:30.000ZRealistic Timelines for Pharma Manufacturing Reshoringhttps://www.pharmaradar360.com/article/beyond-attendance-listening-to-children-and-families-about-the-mental-health-sup-8fc7dce79d8042a8Pharma Surgeen2026-07-02T09:59:50.000ZBeyond attendance: Listening to children and families about the mental health support needs of young people not in schoolhttps://www.pharmaradar360.com/article/ipsen-to-buy-swiss-biotech-memo-in-deal-that-could-top-800-million-73876289c22bac33Pharma Surgeen2026-07-02T09:57:40.000ZIpsen to Buy Swiss Biotech Memo in Deal That Could Top $800 Millionhttps://www.pharmaradar360.com/article/tracking-cathie-wood-major-circle-accumulation-and-biotech-cluster-build-up-trim-5a2141d13eb1b68bPharma Surgeen2026-07-02T09:34:59.000ZTracking Cathie Wood: Major Circle Accumulation and Biotech Cluster Build-Up, Trimming Alibaba and Medical Devicehttps://www.pharmaradar360.com/article/abivax-shares-continue-climbing-after-biotech-firm-moves-to-bolster-balance-shee-e082d08952be37f3Pharma Surgeen2026-07-02T09:25:00.000ZAbivax Shares Continue Climbing After Biotech Firm Moves to Bolster Balance Sheethttps://www.pharmaradar360.com/article/takeda-insilico-strike-ai-drug-discovery-deal-worth-up-to-600-million-8a76d8e84b7c667aPharma Surgeen2026-07-02T09:22:00.000ZTakeda, Insilico Strike AI Drug-Discovery Deal Worth Up to $600 Millionhttps://www.pharmaradar360.com/article/adult-social-care-client-level-data-england-quarterly-update-to-march-2026-f6bcfb810bad2e74Pharma Surgeen2026-07-02T09:11:07.000ZAdult social care client level data, England: quarterly update to March 2026https://www.pharmaradar360.com/article/new-data-strengthen-cemdisiran-case-in-generalized-mg-e8cb98717488cc34Pharma Surgeen2026-07-02T09:09:55.000ZNew data strengthen cemdisiran case in generalized MGhttps://www.pharmaradar360.com/article/fe68bc0b69958ecaPharma Surgeen2026-07-02T09:02:37.000ZΠΡΟΚΗΡΥΞΗ ΠΛΗΡΩΣΗΣ ΘΕΣΕΩΝhttps://www.pharmaradar360.com/article/can-fite-to-test-namodenoson-in-pancreatic-cancer-d5955ad87e627e35Pharma Surgeen2026-07-02T09:02:20.000ZCan-Fite to test namodenoson in pancreatic cancerhttps://www.pharmaradar360.com/article/china-s-cspc-pharmaceutical-group-to-partner-with-astrazeneca-for-renal-disease-03b24634f4a67ca2Pharma Surgeen2026-07-02T08:55:31.000ZChina's CSPC Pharmaceutical Group to partner with AstraZeneca for renal disease drug